Clinical Trial

Post Market Clinical Follow-up of EUROSTEM Femoral Stem

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
EUROSSTEM is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-07-30; most recent amendment 2024-02-16.
Status change: Recruiting → Active, Not Recruiting 2023-01-09
Trial Details
NCT Number NCT04995822
Lead Sponsor EUROS
Conditions Hip Osteoarthritis, Hip Arthropathy, Hip Arthritis, Hip Necrosis, Hip Fractures, Hip Dysplasia
Enrollment 131 participants
Start Date 2021-05-21
Primary Completion 2022-11-06 (estimated)
Study Completion 2032-11-06 (estimated)
Updated on ClinicalTrials.gov 2024-02-20